LENZ Therapeutics, Inc. (NASDAQ: LENZ), a pioneering player in the biotechnology sector, has been gaining attention for its bold venture into presbyopia treatment—a common vision condition affecting millions globally. With a market cap of $405.83 million and a current stock price of $12.97, LENZ presents a fascinating case for investors seeking substantial growth opportunities in the healthcare landscape.

Operating out of Solana Beach, California, LENZ Therapeutics is dedicated to advancing eye-care therapies, specifically focusing on its promising product candidates, LNZ100 and LNZ101. Both are in Phase III clinical trials and are aimed at addressing presbyopia, a key unmet medical need, which could position LENZ as a potential…